New Key Publication: Cholangiopathy and biliary fibrosis in Cyp2c70-deficient mice are fully reversed by ursodeoxycholic acid

Authors: J.F. de Boer, H.D. de Vries, A. Palmiotti, R. Li, M. Doestzada, J.A. Hoogerland, J. Fu, A.M. La Rose, M. Westerterp, N.L. Mulder, M.V. Hovingh, M. Koehorst, N.J. Kloosterhuis, J.C. Wolters, V.W. Bloks, J.T. Haas, D. Dombrowicz, B. Staels, B. van de Sluis, F. Kuipers

Bile acids (BAs) aid intestinal fat absorption and exert systemic actions by receptor-mediated signaling. BA receptors have been identified as drug targets for liver diseases. Yet, differences in BA metabolism between humans and mice hamper translation of pre-clinical outcomes. Cyp2c70-ablation in mice prevents synthesis of mouse/rat-specific muricholic acids (MCAs), but potential (patho)physiological consequences of their absence are unknown. We therefore assessed age- and gender-dependent effects of Cyp2c70-deficiency in mice.

Read more: Cholangiopathy and biliary fibrosis in Cyp2c70-deficient mice are fully reversed by ursodeoxycholic acid - Cellular and Molecular Gastroenterology and Hepatology (cmghjournal.org)